BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel. Show more

Location: Modi’in Technology Park, Hevel Modi'in, 7177871, Israel | Website: https://www.biolinerx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

17.49M

52 Wk Range

$2.30 - $35.60

Previous Close

$4.70

Open

$4.58

Volume

21,678

Day Range

$4.51 - $4.72

Enterprise Value

10.19B

Cash

26.37M

Avg Qtr Burn

-8.089M

Insider Ownership

4.08%

Institutional Own.

0.22%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Phase 2

Update

Phase 1

Data readout

Phase 1

Data readout

Motixafortide (BL-8040) w/ zimberelimab Details
Pancreatic cancer, Cancer, Solid tumor/s

IND

Submission

Failed

Discontinued

Motixafortide (BL-8040) (CXCR4 antagonist) Details
Pancreatic cancer, Solid tumor/s, Cancer

Failed

Discontinued

AGI-134 Details
Solid tumor/s, Cancer

Failed

Discontinued